S&P 500   3,971.27
DOW   32,394.25
QQQ   307.12
Walgreens Boots Alliance: Blue Chip, High-Yield Turnaround Story
Nevada Could be the Source for America's Green Future (Ad)
3 Undervalued Dividend Payers For Volatile Market Conditions
Here’s Why Viking Therapeutics Rose Over 50% on Obesity Drug Data
Nevada Could be the Source for America's Green Future (Ad)
Roku And The 20% Rally That’s About To Start 
3 More Downgrades To Put On Your Buy List 
Lithium Could Be 2023's Next Big Surprise (Ad)
The Bottom Is In For McCormick & Company
Buffett's company owns nearly 24% of Occidental Petroleum
S&P 500   3,971.27
DOW   32,394.25
QQQ   307.12
Walgreens Boots Alliance: Blue Chip, High-Yield Turnaround Story
Nevada Could be the Source for America's Green Future (Ad)
3 Undervalued Dividend Payers For Volatile Market Conditions
Here’s Why Viking Therapeutics Rose Over 50% on Obesity Drug Data
Nevada Could be the Source for America's Green Future (Ad)
Roku And The 20% Rally That’s About To Start 
3 More Downgrades To Put On Your Buy List 
Lithium Could Be 2023's Next Big Surprise (Ad)
The Bottom Is In For McCormick & Company
Buffett's company owns nearly 24% of Occidental Petroleum
S&P 500   3,971.27
DOW   32,394.25
QQQ   307.12
Walgreens Boots Alliance: Blue Chip, High-Yield Turnaround Story
Nevada Could be the Source for America's Green Future (Ad)
3 Undervalued Dividend Payers For Volatile Market Conditions
Here’s Why Viking Therapeutics Rose Over 50% on Obesity Drug Data
Nevada Could be the Source for America's Green Future (Ad)
Roku And The 20% Rally That’s About To Start 
3 More Downgrades To Put On Your Buy List 
Lithium Could Be 2023's Next Big Surprise (Ad)
The Bottom Is In For McCormick & Company
Buffett's company owns nearly 24% of Occidental Petroleum
S&P 500   3,971.27
DOW   32,394.25
QQQ   307.12
Walgreens Boots Alliance: Blue Chip, High-Yield Turnaround Story
Nevada Could be the Source for America's Green Future (Ad)
3 Undervalued Dividend Payers For Volatile Market Conditions
Here’s Why Viking Therapeutics Rose Over 50% on Obesity Drug Data
Nevada Could be the Source for America's Green Future (Ad)
Roku And The 20% Rally That’s About To Start 
3 More Downgrades To Put On Your Buy List 
Lithium Could Be 2023's Next Big Surprise (Ad)
The Bottom Is In For McCormick & Company
Buffett's company owns nearly 24% of Occidental Petroleum
NASDAQ:SPPI

Spectrum Pharmaceuticals - SPPI Stock Forecast, Price & News

$0.67
-0.01 (-1.47%)
(As of 03/28/2023 12:00 AM ET)
Add
Compare
Today's Range
$0.66
$0.71
50-Day Range
$0.54
$1.07
52-Week Range
$0.32
$1.57
Volume
1.70 million shs
Average Volume
1.48 million shs
Market Capitalization
$136.15 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$2.44

Spectrum Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
263.8% Upside
$2.44 Price Target
Short Interest
Healthy
2.36% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.75
Upright™ Environmental Score
News Sentiment
0.07mentions of Spectrum Pharmaceuticals in the last 14 days
Based on 22 Articles This Week
Insider Trading
Selling Shares
$126,073 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.20) to ($0.04) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.18 out of 5 stars

Medical Sector

485th out of 1,002 stocks

Pharmaceutical Preparations Industry

229th out of 488 stocks


SPPI stock logo

About Spectrum Pharmaceuticals (NASDAQ:SPPI) Stock

Spectrum Pharmaceuticals, Inc. is a biotechnology company, which engages in the acquisition, development and commercialization of a pipeline of novel and targeted oncology therapies. Its product pipeline includes: Eflapegrastim, Poziotinib, and IGN002. The company was founded in December 1987 and is headquartered in Henderson, NV.

Receive SPPI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Spectrum Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

SPPI Stock News Headlines

Lithium Could Be 2023's Next Big Surprise
Lithium is the hottest commodity for our green future
Q4 2022 Spectrum Pharmaceuticals Inc Earnings Call
Lithium Could Be 2023's Next Big Surprise
Lithium is the hottest commodity for our green future
See More Headlines
Receive SPPI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Spectrum Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

SPPI Company Calendar

Last Earnings
11/10/2021
Today
3/28/2023
Next Earnings (Estimated)
5/11/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:SPPI
CUSIP
84763A10
Employees
163
Year Founded
2002

Price Target and Rating

Average Stock Price Forecast
$2.44
High Stock Price Forecast
$4.00
Low Stock Price Forecast
$0.75
Forecasted Upside/Downside
+263.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
4 Analysts

Profitability

Net Income
$-75,400,000.00
Pretax Margin
-771.78%

Debt

Sales & Book Value

Annual Sales
$10.11 million
Book Value
$0.15 per share

Miscellaneous

Free Float
197,719,000
Market Cap
$136.15 million
Optionable
Optionable
Beta
2.26

Social Links


Key Executives

  • Thomas J. RigaThomas J. Riga
    President, Chief Executive Officer & Director
  • Nora E. Brennan
    Chief Financial Officer, Director & Executive VP
  • Shanta P. Chawla
    Vice President-Clinical Development
  • Keith M. McGahanKeith M. McGahan
    Secretary, Chief Legal Officer & Executive VP
  • Michael A. Grabow
    Senior VP-Corporate Strategy & Operations













SPPI Stock - Frequently Asked Questions

Should I buy or sell Spectrum Pharmaceuticals stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Spectrum Pharmaceuticals in the last twelve months. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" SPPI shares.
View SPPI analyst ratings
or view top-rated stocks.

What is Spectrum Pharmaceuticals' stock price forecast for 2023?

4 brokers have issued 12 month target prices for Spectrum Pharmaceuticals' shares. Their SPPI share price forecasts range from $0.75 to $4.00. On average, they expect the company's stock price to reach $2.44 in the next year. This suggests a possible upside of 263.8% from the stock's current price.
View analysts price targets for SPPI
or view top-rated stocks among Wall Street analysts.

How have SPPI shares performed in 2023?

Spectrum Pharmaceuticals' stock was trading at $0.3685 at the beginning of 2023. Since then, SPPI stock has increased by 81.8% and is now trading at $0.67.
View the best growth stocks for 2023 here
.

When is Spectrum Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 11th 2023.
View our SPPI earnings forecast
.

How were Spectrum Pharmaceuticals' earnings last quarter?

Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) released its quarterly earnings results on Wednesday, November, 10th. The biotechnology company reported ($0.21) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.28) by $0.07. During the same quarter last year, the business posted ($0.37) earnings per share.

What guidance has Spectrum Pharmaceuticals issued on next quarter's earnings?

Spectrum Pharmaceuticals issued an update on its fourth quarter 2022 earnings guidance on Tuesday, January, 31st. The company provided EPS guidance of for the period. The company issued revenue guidance of $10.00 million-$10.00 million, compared to the consensus revenue estimate of $3.82 million.

What is Joseph Turgeon's approval rating as Spectrum Pharmaceuticals' CEO?

2 employees have rated Spectrum Pharmaceuticals Chief Executive Officer Joseph Turgeon on Glassdoor.com. Joseph Turgeon has an approval rating of 47% among the company's employees. This puts Joseph Turgeon in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Spectrum Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Spectrum Pharmaceuticals investors own include Inovio Pharmaceuticals (INO), Verastem (VSTM), Exelixis (EXEL), SCYNEXIS (SCYX), TG Therapeutics (TGTX), Advanced Micro Devices (AMD), OPKO Health (OPK), Bausch Health Companies (BHC), Sorrento Therapeutics (SRNE) and Zynerba Pharmaceuticals (ZYNE).

What is Spectrum Pharmaceuticals' stock symbol?

Spectrum Pharmaceuticals trades on the NASDAQ under the ticker symbol "SPPI."

Who are Spectrum Pharmaceuticals' major shareholders?

Spectrum Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include Armistice Capital LLC (9.03%), Geode Capital Management LLC (0.80%), Morgan Stanley (0.68%), Millennium Management LLC (0.67%), Renaissance Technologies LLC (0.57%) and CM Management LLC (0.36%). Insiders that own company stock include Francois Lebel, Jeff L Vacirca, Joseph W Turgeon, Keith M Mcgahan, Kurt A Gustafson, Nora Brennan, Seth H Z Fischer, Thomas J Riga and William Ashton.
View institutional ownership trends
.

How do I buy shares of Spectrum Pharmaceuticals?

Shares of SPPI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Spectrum Pharmaceuticals' stock price today?

One share of SPPI stock can currently be purchased for approximately $0.67.

How much money does Spectrum Pharmaceuticals make?

Spectrum Pharmaceuticals (NASDAQ:SPPI) has a market capitalization of $136.15 million and generates $10.11 million in revenue each year. The biotechnology company earns $-75,400,000.00 in net income (profit) each year or ($0.43) on an earnings per share basis.

How many employees does Spectrum Pharmaceuticals have?

The company employs 163 workers across the globe.

How can I contact Spectrum Pharmaceuticals?

Spectrum Pharmaceuticals' mailing address is 11500 SOUTH EASTERN AVENUE SUITE 240, HENDERSON NV, 89052. The official website for the company is www.sppirx.com. The biotechnology company can be reached via phone at (702) 835-6300, via email at ir@sppirx.com, or via fax at 702-260-7405.

This page (NASDAQ:SPPI) was last updated on 3/29/2023 by MarketBeat.com Staff